ReviewDrug design, development and therapy2025
Therapeutic Targeting of PPARγ in Nonalcoholic Fatty Liver Disease: Efficacy, Safety, and Drug Development.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Pterostilbene Combating Cyclophosphamide-Induced Central Neuro-Inflammation in Rats: Effect on GFAP, PPAR- γ, NLRP3, COX-2 and Nrf2/HO-1 Pathway.Biomedicines · 2026Article
- Vitamin E administration reduces liver enzyme levels in patients with Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD): evidence from a systematic review and meta-analysis.Nutrition & metabolism · 2026Review
- Screening and identification of the ncRNA-mRNA regulatory network associated with DNA methylation in goose embryonic myoblasts.BMC genomics · 2026Article
- Metabolism-Associated Hepatotoxicity of Gatifloxacin in Zebrafish Larvae.Biomolecules · 2026Article
- Palmitoleic acid loss links pulmonary dysbiosis to lung injury after single-lung ventilation.American journal of respiratory cell and molecular biology · 2026Article
- Hnf1aos1 as a Metabolic Coordinator of Hepatic Lipid Homeostasis and Feedback Control.Non-coding RNA · 2026Article
- Residual bile flow shapes PPARγ-mediated antifibrotic responses in experimental segmental cholestasis.Scientific reports · 2026Article
- Prussian blue analogue-mineralized ginseng-derived vesicles promote PPARγ nuclear translocation to suppress tumor vasculogenic mimicry and reverse the immunosuppressive microenvironment.Journal of nanobiotechnology · 2026Article
- Review
- Mechanistic insights into the lipotropic and atheroprotective effects of rosuvastatin-loaded glycerosomes in dyslipidemic rats.Scientific reports · 2026Article
- IBDkb: an AI-enhanced integrative knowledge base for inflammatory bowel disease research and drug discovery.Database : the journal of biological databases and curation · 2026Article
- PPARγ: a key orchestrator of epidermal barrier, immune responses, and lipid metabolism in atopic dermatitis pathogenesis and therapy.Frontiers in allergy · 2026Review
- Immune crosstalk in metabolic dysfunction-associated steatotic liver disease: interactions between innate and adaptive immunity.Frontiers in immunology · 2026Review
- Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease.Frontiers in cell and developmental biology · 2026Review
- Lipid metabolism-MAFLD crosstalk: mechanisms and therapy.Frontiers in endocrinology · 2026Review
- Liquiritin restores metabolic homeostasis in NAFLD by modulating AKT1/FOXO1 signaling.Frontiers in pharmacology · 2026Article
- Article
- Improvement of Liver Fibrosis in Patients with MASLD Undergoing Pioglitazone Treatment: An Update.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a metabolic-associated liver disorder characterized by a multi-faceted pathological progression involving fat accumulation, oxidative stress, and inflammation. Peroxisome proliferator-activated receptor gamma (PPARγ), a key nuclear receptor involved in lipid metabolism, insulin sensitivity regulation, and immune modulation, plays a significant role in both the development and treatment of NAFLD. This review summarizes the physiological functions of PPARγ in tissues such as adipose tissue, pancreas, intestine, and liver. Furthermore, it compiles current clinical research progress on PPARγ agonists, including mono-agonists, dual agonists, and pan-agonists, and analyzes their associated side effects, mechanisms of occurrence, and potential solutions. Importantly, therapeutic strategies targeting PPARγ hold promise for improving steatosis and insulin resistance and inhibiting liver fibrosis. Future research is needed to further explore the influence of blood insulin levels, hepatic PPARγ levels, and tissue-specific factors on the therapeutic efficacy of PPARγ agonists. Besides, the development of novel PPAR multi-agonists, partial PPARγ agonists, and combination therapies should be explored to optimize therapeutic outcomes while minimizing adverse effects, thereby providing new directions for precision medical interventions in NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.